Navigation Links
Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
Date:9/2/2008

in 2009.

-- In July 2008, HGS initiated dosing in the safety lead-in to a randomized Phase 2 trial of HGS-ETR1 in combination with Nexavar (sorafenib) in patients with advanced hepatocellular cancer, which accounts for 80-90% of all liver cancers.

These three trials, taken together, will support a decision on whether to advance HGS-ETR1 to Phase 3 development. It also is possible that a sufficiently positive result from any one of the trials could lead to a Phase 3 decision for that specific indication.

About Multiple Myeloma

Multiple myeloma is a cancer of the plasma cells in bone marrow. In the United States each year, there are approximately 11,000 deaths from multiple myeloma, with approximately 16,000 new cases diagnosed. It accounts for about 10% of all hematologic cancers.

About HGS-ETR1

HGS-ETR1 (mapatumumab) is an agonistic human monoclonal antibody that directly induces cancer-cell death by specifically binding to and activating the protein known as TRAIL receptor 1. Using genomic techniques, HGS originally identified the TRAIL receptor 1 protein. The HGS-ETR1 antibody was generated by HGS through collaboration with Cambridge Antibody Technology. HGS is developing HGS-ETR1 as a potential treatment for a broad range of cancers.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa- 2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is o
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)...  The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization.  ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... New to Antiretroviral Therapy Respond ... Similarly to Men and ... once-daily or twice-daily dosing of Abbott,s (NYSE:,ABT) protease inhibitor Kaletra(R) ... amount of HIV-1),and improving the immune system (increasing CD4 cells) ...
... a,biopharmaceutical company engaged in the discovery and development ... announced today,that Genentech, a collaborator, has moved a ... into a phase 1 clinical trial,that has begun ... and tolerability of both single and multiple doses ...
Cached Medicine Technology:Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3
(Date:7/10/2014)... 11, 2014 Karen Middleton, Executive Director ... CEO of Planned Parenthood of the Rocky Mountains (PPRM), ... Udall and Representative Diana DeGette were in Washington, DC ... Lobby decision and keeping bosses out of women’s birth ... to the president today in Denver addressing issues related ...
(Date:7/10/2014)... The Capital Institute for Neurosciences at ... procedure in a clinical trial that delivers chemotherapy to ... , During the procedure, done at Capital Health Medical ... threaded a tiny catheter through the patient’s femoral artery ... and into the brain. Once the catheter reached the ...
(Date:7/10/2014)... 3 fatty acids had healthier joints than those fed ... acids, according to Duke Medicine researchers. , The findings, ... (10.1136/annrheumdis-2014-205601) on July 11, 2014, suggest that unhealthy ... to worsening osteoarthritis. , "Our results suggest that dietary ... in the link between obesity and osteoarthritis," said Farshid ...
(Date:7/10/2014)... More than 200 experts on aggression, who ... violence, will attend the 21st World Meeting of the ... at the Loews Atlanta Hotel, July 15-19. , ... meeting, which is held every other year on alternating ... leading scholars from more than 20 different countries, which ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... account for an increasing number of accidents in ... in Safety Reboot. The articles highlight safety issues ... estimated 317 million accidents occur on the job ... Three features continue to explore "preventable workplace accidents." ...
Breaking Medicine News(10 mins):Health News:Naral Pro-Choice Colorado & Planned Parenthood Of The Rocky Mountains Statement On Udall & Degette Staying In Dc To Introduce Legislation 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Georgia State Hosts National Conference On Aggression 2Health News:Georgia State Hosts National Conference On Aggression 3Health News:Georgia State Hosts National Conference On Aggression 4Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3
... the Black Death as the world's worst pandemic if the ... get life prolonging drugs. The illness has killed 25 million ... infected each day with HIV, which destroys the immune system. ... will die, pushing the death toll beyond the 40 million ...
... suffer from asphyxia, which can lead to brain injury, multiple ... cent of babies who suffer from a moderate lack of ... no effective treatments to reduce the risk of asphyxia at ... a baby's temperature may have beneficial effects. ,UK researchers ...
... in the alpha gene are the cause of premature menopause ... about 2% of the total population. ,The University of ... of a genetic test, which would allow women// with a ... at risk. They analysed DNA from women who had experienced ...
... undergoing coronary artery bypass surgery is rising, even though ... artery bypass surgery uses a blood vessel from another ... or clogged arteries in the heart. A buildup of ... known as atherosclerosis. ,In the new study, ...
... FDA issued a statement about the potential for depression and ... reports say that the 15-year-old pilot who crashed his plane ... investigators don't know whether or not the teen, Charles J. ... death. Blood tests should reveal if the drug was in ...
... from the Institute of Health Sciences in Oxford found that ... likely to have a stillbirth, or to develop pre-eclampsia.// Taking ... the researchers. ,The researchers reviewed more than 23 ... benefits of anti-platelet drugs, of which low-dose aspirin is the ...
Cached Medicine News:
... precise and accurate Measurements! ,Patients are impressed ... examination when they see the doctor is ... - after only 5 minutes of proper ... proficient in the operation of this instrument ...
Great for small incisions and excision needs...
Multi-sided, Sharp all around...
...
Medicine Products: